The Zurich-based biotech company, located in the Bio-Technopark in Schlieren-Zurich, Switzerland, is dedicated to developing tumor-selective immunotherapies by creating MHC-specific antibodies that target tumor-specific intracellular antigens. CDR-Life's technology allows healthcare providers to offer targeted treatment to cancer patients, with a particular focus on immuno-oncology and ophthalmology.